Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis

American Journal of Medical Genetics, Part A

Volumn 164, Issue 6, 2014, Pages 1431-1437

  Merker, Vanessa L ^a   Bredella, Miriam A ^a   Cai, Wenli ^a   Kassarjian, Ara ^b   Harris, Gordon J ^a   Muzikansky, Alona ^a   Nguyen, Rosa ^c,d   Mautner, Victor F ^d   Plotkin, Scott R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b SL ^*  (Spain)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Nerve sheath tumor; Neurofibromatosis 1; Neurofibromatosis 2; Pain; Quality of life; Schwannomatosis; SF 36; Whole body MRI

Indexed keywords

ADULT; AGED; ARTICLE; CORRELATION COEFFICIENT; DEMOGRAPHY; FEMALE; GENETIC DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PAIN; PHENOTYPE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCHWANNOMATOSIS; SHORT FORM 36; STUDENT T TEST; TUMOR VOLUME; VISUAL ANALOG SCALE; ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COMPLICATION; MIDDLE AGED; NERVE SHEATH TUMOR; NEURILEMOMA; PAIN MEASUREMENT; PATHOLOGY; PSYCHOLOGY; RADIOGRAPHY; SKIN TUMOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVE SHEATH NEOPLASMS; NEURILEMMOMA; NEUROFIBROMATOSES; NEUROFIBROMATOSIS 1; NEUROFIBROMATOSIS 2; PAIN; PAIN MEASUREMENT; QUALITY OF LIFE; QUESTIONNAIRES; SKIN NEOPLASMS; TUMOR BURDEN; YOUNG ADULT;

EID: 84899968787     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.36466     Document Type: Article

References (23)

1. Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG. 2002. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 59:1759-1765.
2. Cai W, Kassarjian A, Bredella MA, Harris GJ, Yoshida H, Mautner VF, Wenzel R, Plotkin SR. 2009. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: Determination on whole-body MR images. Radiology 250:665-673.
3. Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. 2005. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 26:93-97.
4. Friedman JM. 1999. Epidemiology of neurofibromatosis type 1. Am J Med Genet 89:1-6.
5. Granstrom S, Langenbruch A, Augustin M, Mautner VF. 2012. Psychological burden in adult neurofibromatosis type 1 patients: Impact of disease visibility on body image. Dermatology 224:160-167.
6. Hyman SL, Shores A, North KN. 2005. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 65:1037-1044.
7. Kayl AE, Moore BD III. 2000. Behavioral phenotype of neurofibromatosis, type 1. Ment Retard Dev Disabil Res Rev 6:117-124.
8. Kodra Y, Giustini S, Divona L, Porciello R, Calviei S, Wolkenstein P, Taruscio D. 2009. Health-related quality of life in patients with neurofibromatosis type 1. Dermatology 218:215-220.
9. Lu-Emerson C, Plotkin S. 2009a. The neurofibromatoses. Part 1: NF1. Rev Neurol Dis 6:E47-E53.
10. Lu-Emerson C, Plotkin S. 2009b. The neurofibromatoses. Part 2: NF2 and schwannomatosis. Rev Neurol Dis 6:E81-E86.
11. MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, Lev M, Mautner VF, Niimura M, Plotkin SR, Sang CN, Stemmer-Rachamimov A, Roach ES. 2005. Diagnostic criteria for schwannomatosis. Neurology 64:1838-1845.
12. Mautner VF, Granstrom S, Leark RA. 2012. Impact of ADHD in adults with neurofibromatosis type 1: Associated psychological and social problems. J Atten Disord [Epub ahead of print].
13. Merker VL, Esparza S, Smith MJ, Stemmer-Rachamimov A, Plotkin SR. 2012. Clinical features of schwannomatosis: A retrospective analysis of 87 patients. Oncologist 17:1317-1322.
14. Mulvihill JJ, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI, Eldridge R. 1990. NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med 113:39-52.
15. Neary WJ, Hillier VF, Flute T, Stephens SDG, Ramsden RT, Evans DG. 2010a. The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol 35:291-299.
16. Neary WJ, Hillier VF, Flute T, Stephens SD, Ramsden RT, Evans DG. 2010b. The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol 35:291-299.
17. Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P. 2006. Impact of neurofibromatosis 1 on quality of life: A cross-sectional study of 176 American cases. Am J Med Genet Part A 140A:1893-1898.
18. Plotkin SR, Bredella MA, Cai W, Kassarjian A, Harris GJ, Esparza S, Merker VL, Munn LL, Muzikansky A, Askenazi M, Nguyen R, Wenzel R, Mautner VF. 2012. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS ONE 7:e35711.
19. Pride NA, Payne JM, North KN. 2012. The impact of ADHD on the cognitive and academic functioning of children with NF1. Dev Neuropsychol 37:590-600.
20. Saris-Baglama RN, Dewey CJ, Chisholm GB, Plumb E, Kosinski M, Bjorner JB, Ware JE. 2007. QualityMetric Health Outcomes Scoring Software 2.0: User's Guide.
21. Ware JE. 2011. Chapter 14: 2009 normative data. In: Maruish ME, editor. User's manual for the Sf-36v2 health survey, 3rd edition. Lincoln, RI: QualityMetric Incorporated.
22. Ware JE Jr, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish ME. 2007. User's manual for the Sf-36v2 health survey, 2nd edition. Lincoln, RI: QualityMetric Incorporated.
23. Wolkenstein P, Zeller J, Revuz J, Ecosse E, Leplege A. 2001. Quality-of-life impairment in neurofibromatosis type 1: A cross-sectional study of 128 cases. Arch Dermatol 137:1421-1425.